The EEA1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte line, engineered for loss-of-function studies of the EEA1 gene. This product provides a heterogeneous pool of edited cells with targeted disruption of EEA1, enabling analysis of early endosome biology in a B cell context without clonal selection. The polyclonal format preserves population-level diversity and is suitable for bulk functional assays where complete gene inactivation across the entire culture is not required.
Raji cells are an EBV-positive lymphoblastoid B cell line originating from a Burkitt lymphoma patient. They retain key characteristics of mature B lymphocytes, including surface immunoglobulin expression and active endocytic and antigen processing machinery, making them a widely used model for B cell receptor signaling, lymphoma biology, and intracellular trafficking studies. Their robust growth and well-characterized endosomal system provide an ideal background for investigating EEA1-dependent processes.
EEA1 functions as a critical Rab5 effector that binds phosphatidylinositol 3-phosphate (PI3P) on early endosomes, mediating endosome tethering and homotypic fusion essential for endosomal maturation. EEA1 is recruited by Rab5-GTP and PI3P, forming complexes with Rabaptin-5 and syntaxin 13 to drive early endosome fusion. Downstream, EEA1-dependent trafficking governs EGFR degradation, transferrin receptor recycling, and progression to late endosomes and lysosomes via Rab7 and LAMP1. Disruption of EEA1 thus impairs endocytic sorting, leading to altered receptor turnover and lysosomal delivery.
In the Raji B lymphocyte context, loss of EEA1 disrupts key pathways including B cell receptor endocytosis, antigen processing and presentation, and trafficking of antibody-drug conjugates. Given the role of endosomal dynamics in lymphomagenesis and immune cell function, these knockout cells offer a valuable tool for dissecting endocytic control of signaling and for evaluating therapeutics that rely on internalization. The polyclonal population allows assessment of EEA1 loss under conditions of heterogeneous gene inactivation, reflecting more physiologically variable scenarios.
Researchers can employ this model in a variety of assays, including western blotting to confirm EEA1 ablation, immunofluorescence colocalization of EEA1 and Rab5 to monitor early endosome integrity, transferrin uptake assays to quantify receptor recycling, and flow cytometry to measure surface receptor expression dynamics. Co-immunoprecipitation studies with Rab5 further elucidate altered effector interactions. Typical applications include investigating endosomal trafficking mechanisms in B cell lymphomas, screening for modulators of antibody-drug conjugate internalization, and studying antigen processing deficiencies. For further technical information, please contact Ascent Research.
